These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
939 related articles for article (PubMed ID: 16227402)
21. Role of mTOR in the degradation of IRS-1: regulation of PP2A activity. Hartley D; Cooper GM J Cell Biochem; 2002; 85(2):304-14. PubMed ID: 11948686 [TBL] [Abstract][Full Text] [Related]
22. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Tamburini J; Chapuis N; Bardet V; Park S; Sujobert P; Willems L; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D Blood; 2008 Jan; 111(1):379-82. PubMed ID: 17878402 [TBL] [Abstract][Full Text] [Related]
23. Mammalian target of rapamycin is activated in association with myometrial proliferation during pregnancy. Jaffer S; Shynlova O; Lye S Endocrinology; 2009 Oct; 150(10):4672-80. PubMed ID: 19589861 [TBL] [Abstract][Full Text] [Related]
24. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631 [TBL] [Abstract][Full Text] [Related]
25. Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Frost P; Shi Y; Hoang B; Gera J; Lichtenstein A Mol Cancer Ther; 2009 Jan; 8(1):83-93. PubMed ID: 19139116 [TBL] [Abstract][Full Text] [Related]
26. Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by Serine 312 phosphorylation. Greene MW; Sakaue H; Wang L; Alessi DR; Roth RA J Biol Chem; 2003 Mar; 278(10):8199-211. PubMed ID: 12510059 [TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Ge NL; Rudikoff S Blood; 2000 Oct; 96(8):2856-61. PubMed ID: 11023522 [TBL] [Abstract][Full Text] [Related]
28. Prostaglandin F2alpha represses IGF-I-stimulated IRS1/phosphatidylinositol-3-kinase/AKT signaling in the corpus luteum: role of ERK and P70 ribosomal S6 kinase. Arvisais E; Hou X; Wyatt TA; Shirasuna K; Bollwein H; Miyamoto A; Hansen TR; Rueda BR; Davis JS Mol Endocrinol; 2010 Mar; 24(3):632-43. PubMed ID: 20160123 [TBL] [Abstract][Full Text] [Related]
29. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer. Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027 [TBL] [Abstract][Full Text] [Related]
30. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Tai YT; Podar K; Catley L; Tseng YH; Akiyama M; Shringarpure R; Burger R; Hideshima T; Chauhan D; Mitsiades N; Richardson P; Munshi NC; Kahn CR; Mitsiades C; Anderson KC Cancer Res; 2003 Sep; 63(18):5850-8. PubMed ID: 14522909 [TBL] [Abstract][Full Text] [Related]
31. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583 [TBL] [Abstract][Full Text] [Related]
32. PKCdelta and mTOR interact to regulate stress and IGF-I induced IRS-1 Ser312 phosphorylation in breast cancer cells. Mingo-Sion AM; Ferguson HA; Koller E; Reyland ME; Van Den Berg CL Breast Cancer Res Treat; 2005 Jun; 91(3):259-69. PubMed ID: 15952059 [TBL] [Abstract][Full Text] [Related]
33. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Wan X; Harkavy B; Shen N; Grohar P; Helman LJ Oncogene; 2007 Mar; 26(13):1932-40. PubMed ID: 17001314 [TBL] [Abstract][Full Text] [Related]
34. Mono- or dual-phosphorylation of akt kinase is regulated by distinct receptors that involve the common insulin receptor substrate. Schnyder B; Lahm H; Pittet M; Schnyder-Candrian S J Recept Signal Transduct Res; 2002; 22(1-4):213-28. PubMed ID: 12503617 [TBL] [Abstract][Full Text] [Related]
35. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867 [TBL] [Abstract][Full Text] [Related]
36. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051 [TBL] [Abstract][Full Text] [Related]
37. AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Ning J; Clemmons DR Mol Endocrinol; 2010 Jun; 24(6):1218-29. PubMed ID: 20363874 [TBL] [Abstract][Full Text] [Related]
38. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641 [TBL] [Abstract][Full Text] [Related]